Autologous transplantation of hematopoietic stem cells has recently been proposed as a possible treatment for autoimmune diseases that are associated with a very severe prognosis. A 12-year-old girl who, since 4 years of age, had systemic sclerosis with progressive pulmonary involvement underwent autologous peripheral blood-derived stem cell transplantation (aPBSCT) using CD34+ selection, cyclophosphamide, and the infusion of the monoclonal antibody CAMPATH-1G. Following transplantation, in the absence of any treatment other than symptomatic therapy, the patient's exertional dyspnea and alveolitis disappeared and she experienced a marked improvement in skin score, height velocity, and general well-being that has persisted 2 years after the transplantation procedure. Autologous PBSCT associated with the infusion of the monoclonal antibody CAMPATH-1G appears to be a useful therapy for otherwise intractable forms of progressive systemic sclerosis.

Martini, A., Maccario, R., Ravelli, A., Montagna, D., De Benedetti, F., Bonetti, F., Viola, S., Zecca, M., Perotti, C., Locatelli, F., Marked and sustained improvement two years after autologous stem cell transplantation in a girl with systemic sclerosis, <<ARTHRITIS AND RHEUMATISM>>, 1999; 42 (4): 807-811. [doi:10.1002/1529-0131(199904)42:4<807::AID-ANR26>3.0.CO;2-T] [https://hdl.handle.net/10807/263703]

Marked and sustained improvement two years after autologous stem cell transplantation in a girl with systemic sclerosis

Locatelli, Franco
1999

Abstract

Autologous transplantation of hematopoietic stem cells has recently been proposed as a possible treatment for autoimmune diseases that are associated with a very severe prognosis. A 12-year-old girl who, since 4 years of age, had systemic sclerosis with progressive pulmonary involvement underwent autologous peripheral blood-derived stem cell transplantation (aPBSCT) using CD34+ selection, cyclophosphamide, and the infusion of the monoclonal antibody CAMPATH-1G. Following transplantation, in the absence of any treatment other than symptomatic therapy, the patient's exertional dyspnea and alveolitis disappeared and she experienced a marked improvement in skin score, height velocity, and general well-being that has persisted 2 years after the transplantation procedure. Autologous PBSCT associated with the infusion of the monoclonal antibody CAMPATH-1G appears to be a useful therapy for otherwise intractable forms of progressive systemic sclerosis.
1999
Inglese
Martini, A., Maccario, R., Ravelli, A., Montagna, D., De Benedetti, F., Bonetti, F., Viola, S., Zecca, M., Perotti, C., Locatelli, F., Marked and sustained improvement two years after autologous stem cell transplantation in a girl with systemic sclerosis, <<ARTHRITIS AND RHEUMATISM>>, 1999; 42 (4): 807-811. [doi:10.1002/1529-0131(199904)42:4<807::AID-ANR26>3.0.CO;2-T] [https://hdl.handle.net/10807/263703]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/263703
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 51
social impact